The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Autoimmune Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental factors or infections.
The global Autoimmune Drugs market size is expected to reach US$ 131730 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Autoimmune Drugs in various end use industries. The expanding demands from the Hospitals, Homecare and Specialty Clinics,, are propelling Autoimmune Drugs market. Rheumatoid Arthritis (RA), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Multiple Sclerosis (MS) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Autoimmune Drugs market, driven by demand from China, the second largest economy with some signs of stabilising, the Autoimmune Drugs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Autoimmune Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Autoimmune Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Autoimmune Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Autoimmune Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Autoimmune Drugs covered in this report include Eli Lilly, GSK, AbbVie, Johnson & Johnson, Biogen, Amgen, Pfizer, Roche and Baxter, etc.
The global Autoimmune Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
GSK
AbbVie
Johnson & Johnson
Biogen
Amgen
Pfizer
Roche
Baxter
Global Autoimmune Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Autoimmune Drugs market, Segment by Type:
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Psoriasis
Inflammatory Bowel Disease (IBD)
Ankylosing Spondylitis (AS)
Systemic Lupus Erythematosus (SLE)
Global Autoimmune Drugs market, by Application
Hospitals
Homecare
Specialty Clinics
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Autoimmune Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Autoimmune Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Abnormal immune responses of the innate immune system can cause autoimmune diseases, which can damage body tissues and lead to abnormal organ functions. Immunological complications due to physiological processes within the human body lead to autoimmune diseases. These diseases are characterized by chronic inflammatory processes that activate the innate immune system and the production of antibodies that destroy host tissues. These inflammatory processes can be caused by genetic or environmental factors or infections.
The global Autoimmune Drugs market size is expected to reach US$ 131730 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The market is mainly driven by the significant applications of Autoimmune Drugs in various end use industries. The expanding demands from the Hospitals, Homecare and Specialty Clinics,, are propelling Autoimmune Drugs market. Rheumatoid Arthritis (RA), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Multiple Sclerosis (MS) segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Autoimmune Drugs market, driven by demand from China, the second largest economy with some signs of stabilising, the Autoimmune Drugs market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Autoimmune Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Autoimmune Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Autoimmune Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Autoimmune Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Autoimmune Drugs covered in this report include Eli Lilly, GSK, AbbVie, Johnson & Johnson, Biogen, Amgen, Pfizer, Roche and Baxter, etc.
The global Autoimmune Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Eli Lilly
GSK
AbbVie
Johnson & Johnson
Biogen
Amgen
Pfizer
Roche
Baxter
Global Autoimmune Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Autoimmune Drugs market, Segment by Type:
Rheumatoid Arthritis (RA)
Multiple Sclerosis (MS)
Psoriasis
Inflammatory Bowel Disease (IBD)
Ankylosing Spondylitis (AS)
Systemic Lupus Erythematosus (SLE)
Global Autoimmune Drugs market, by Application
Hospitals
Homecare
Specialty Clinics
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Autoimmune Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Autoimmune Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Autoimmune Drugs Market Overview
1.1 Autoimmune Drugs Product Overview
1.2 Autoimmune Drugs Market Segment by Type
1.2.1 Rheumatoid Arthritis (RA)
1.2.2 Multiple Sclerosis (MS)
1.2.3 Psoriasis
1.2.4 Inflammatory Bowel Disease (IBD)
1.2.5 Ankylosing Spondylitis (AS)
1.2.6 Systemic Lupus Erythematosus (SLE)
1.3 Global Autoimmune Drugs Market Size by Type
1.3.1 Global Autoimmune Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Autoimmune Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Autoimmune Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Autoimmune Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Autoimmune Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Autoimmune Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Autoimmune Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Autoimmune Drugs Sales Breakdown by Type (2018-2023)
2 Global Autoimmune Drugs Market Competition by Company
2.1 Global Top Players by Autoimmune Drugs Sales (2018-2023)
2.2 Global Top Players by Autoimmune Drugs Revenue (2018-2023)
2.3 Global Top Players by Autoimmune Drugs Price (2018-2023)
2.4 Global Top Manufacturers Autoimmune Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Autoimmune Drugs Market Competitive Situation and Trends
2.5.1 Autoimmune Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Autoimmune Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Autoimmune Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Autoimmune Drugs Market
2.8 Key Manufacturers Autoimmune Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Autoimmune Drugs Status and Outlook by Region
3.1 Global Autoimmune Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Autoimmune Drugs Historic Market Size by Region
3.2.1 Global Autoimmune Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Autoimmune Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Autoimmune Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Autoimmune Drugs Forecasted Market Size by Region
3.3.1 Global Autoimmune Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Autoimmune Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Autoimmune Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Autoimmune Drugs by Application
4.1 Autoimmune Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Homecare
4.1.3 Specialty Clinics
4.2 Global Autoimmune Drugs Market Size by Application
4.2.1 Global Autoimmune Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Autoimmune Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Autoimmune Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Autoimmune Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Autoimmune Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Autoimmune Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Autoimmune Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Autoimmune Drugs Sales Breakdown by Application (2018-2023)
5 North America Autoimmune Drugs by Country
5.1 North America Autoimmune Drugs Historic Market Size by Country
5.1.1 North America Autoimmune Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Autoimmune Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Autoimmune Drugs Sales in Value by Country (2018-2023)
5.2 North America Autoimmune Drugs Forecasted Market Size by Country
5.2.1 North America Autoimmune Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Autoimmune Drugs Sales in Value by Country (2024-2029)
6 Europe Autoimmune Drugs by Country
6.1 Europe Autoimmune Drugs Historic Market Size by Country
6.1.1 Europe Autoimmune Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Autoimmune Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Autoimmune Drugs Sales in Value by Country (2018-2023)
6.2 Europe Autoimmune Drugs Forecasted Market Size by Country
6.2.1 Europe Autoimmune Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Autoimmune Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Autoimmune Drugs by Region
7.1 Asia-Pacific Autoimmune Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Autoimmune Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Autoimmune Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Autoimmune Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Autoimmune Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Autoimmune Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Autoimmune Drugs Sales in Value by Region (2024-2029)
8 Latin America Autoimmune Drugs by Country
8.1 Latin America Autoimmune Drugs Historic Market Size by Country
8.1.1 Latin America Autoimmune Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Autoimmune Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Autoimmune Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Autoimmune Drugs Forecasted Market Size by Country
8.2.1 Latin America Autoimmune Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Autoimmune Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Autoimmune Drugs by Country
9.1 Middle East and Africa Autoimmune Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Autoimmune Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Autoimmune Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Autoimmune Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Autoimmune Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Autoimmune Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Autoimmune Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Information
10.1.2 Eli Lilly Introduction and Business Overview
10.1.3 Eli Lilly Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Eli Lilly Autoimmune Drugs Products Offered
10.1.5 Eli Lilly Recent Development
10.2 GSK
10.2.1 GSK Company Information
10.2.2 GSK Introduction and Business Overview
10.2.3 GSK Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GSK Autoimmune Drugs Products Offered
10.2.5 GSK Recent Development
10.3 AbbVie
10.3.1 AbbVie Company Information
10.3.2 AbbVie Introduction and Business Overview
10.3.3 AbbVie Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 AbbVie Autoimmune Drugs Products Offered
10.3.5 AbbVie Recent Development
10.4 Johnson & Johnson
10.4.1 Johnson & Johnson Company Information
10.4.2 Johnson & Johnson Introduction and Business Overview
10.4.3 Johnson & Johnson Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Johnson & Johnson Autoimmune Drugs Products Offered
10.4.5 Johnson & Johnson Recent Development
10.5 Biogen
10.5.1 Biogen Company Information
10.5.2 Biogen Introduction and Business Overview
10.5.3 Biogen Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Biogen Autoimmune Drugs Products Offered
10.5.5 Biogen Recent Development
10.6 Amgen
10.6.1 Amgen Company Information
10.6.2 Amgen Introduction and Business Overview
10.6.3 Amgen Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Amgen Autoimmune Drugs Products Offered
10.6.5 Amgen Recent Development
10.7 Pfizer
10.7.1 Pfizer Company Information
10.7.2 Pfizer Introduction and Business Overview
10.7.3 Pfizer Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Pfizer Autoimmune Drugs Products Offered
10.7.5 Pfizer Recent Development
10.8 Roche
10.8.1 Roche Company Information
10.8.2 Roche Introduction and Business Overview
10.8.3 Roche Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Roche Autoimmune Drugs Products Offered
10.8.5 Roche Recent Development
10.9 Baxter
10.9.1 Baxter Company Information
10.9.2 Baxter Introduction and Business Overview
10.9.3 Baxter Autoimmune Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Baxter Autoimmune Drugs Products Offered
10.9.5 Baxter Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Autoimmune Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Autoimmune Drugs Industrial Chain Analysis
11.4 Autoimmune Drugs Market Dynamics
11.4.1 Autoimmune Drugs Industry Trends
11.4.2 Autoimmune Drugs Market Drivers
11.4.3 Autoimmune Drugs Market Challenges
11.4.4 Autoimmune Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Autoimmune Drugs Distributors
12.3 Autoimmune Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
